Top Stocks
Best biotech stocks for May 2026
These seven biotech stocks stand out for commercial strength, earnings quality, and pipeline depth, with Amgen leading this May 2026 ranking.
May 27, 202613 MIN
TickerSpark Feed
biotech
Everything tagged "biotech" across research, earnings, and macro.
20 articles
Research ReportROIV
Roivant Sciences (ROIV): Cash-Rich Biotech Catalysts Ahead
Roivant pairs a $4.3B cash base with multiple late-stage catalysts, led by brepocitinib’s near-term launch path and several 2H 2026 readouts. The stock looks like a selective Buy, but execution risk remains high given heavy cash burn and limited current revenue.
May 20, 202623 MIN
Research ReportINSM
Insmed (INSM): BRINSUPRI Launch Drives Premium Growth
Insmed has evolved into a commercial-stage rare respiratory company with two marketed products and a fast-scaling launch. BRINSUPRI is driving the revenue inflection, while ARIKAYCE and a late-stage pipeline add durability and upside.
May 12, 202622 MIN
Research ReportAXSM
Axsome Therapeutics (AXSM): AUVELITY Drives a Premium Growth Story
Axsome has evolved into a commercial CNS growth story, led by AUVELITY’s rapid prescription gains and a newly expanded Alzheimer’s agitation opportunity. The stock looks attractive on execution, but valuation and ongoing losses keep it from being a low-risk idea.
May 4, 202621 MIN
Research ReportAMGN
Amgen (AMGN): Growth Broadens Beyond Patent Cliffs
Amgen is growing through patent expirations with broad-based momentum across Repatha, rare disease, oncology, and biosimilars. The stock looks like a Buy, though valuation already reflects much of the resilience.
May 1, 202621 MIN
Research ReportLLY
Eli Lilly (LLY): Incretin Growth Still Drives the Story
Eli Lilly is delivering exceptional revenue and EPS growth, led by Mounjaro and Zepbound, while raising 2026 guidance again. The stock is expensive, but the franchise momentum and pipeline breadth keep the long-term case intact.
Apr 30, 202627 MIN
Research ReportREGN
Regeneron Pharmaceuticals (REGN): Dupixent Growth Offsets EYLEA Pressure
Regeneron combines a durable cash engine with a broad pipeline, while Dupixent growth and EYLEA HD adoption help offset legacy EYLEA biosimilar pressure. The stock screens as a Buy with valuation still reasonable for a mature biotech compounder.
Apr 29, 202623 MIN
Research ReportTMO
Thermo Fisher Scientific (TMO): Quality Franchise, Price Debate
Thermo Fisher Scientific remains a top-tier life sciences platform with recurring revenue, strong cash flow, and multiple growth catalysts. The stock is a Buy, but the report argues the main question is valuation rather than business quality.
Apr 23, 202628 MIN
On-Demand Research
Need research on a stock not covered here?
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the Generator